接种异源加强型 COVID-19 疫苗 6 个月后针对 SARS-CoV-2 的不同变体（包括奥密克戎）产生的免疫应答。
Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine.
机构信息
Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India.
Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India.
出版信息
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac033.
Abstract
Comparative analysis at one- and six-months post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups. However, significant reduction in NAb titers against Omicron in vaccinees’ sera post-six months underlines need for cautious prospective follow-up.
摘要
接种后 1 个月和 6 个月的比较分析显示，异源和同源疫苗接种组的 S1-RBD IgG 抗体和针对 B.1、Alpha、Beta 和 Delta 变异株的 NAb 滴度均略有下降。然而，接种者血清中 6 个月后针对奥密克戎的 NAb 滴度显著下降，这强调了需要谨慎进行前瞻性随访。
相似文献
1
Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine.接种异源加强型 COVID-19 疫苗 6 个月后针对 SARS-CoV-2 的不同变体（包括奥密克戎）产生的免疫应答。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac033.
2
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).一种鼻内 COVID-19 候选疫苗（BBV154）的初步临床安全性和免疫原性评估，以及 COVAXIN（BBV152）异源初免-加强策略的体液免疫原性评估。
Front Immunol. 2022 Dec 8;13:1063679. doi: 10.3389/fimmu.2022.1063679. eCollection 2022.
3
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
4
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.异源加强 COVID-19 疫苗接种方案的免疫原性和安全性：ChAdOx1 疫苗 Covishield 加 BBV152 疫苗 Covaxin。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab166.
5
Inactivated vaccine Covaxin/BBV152: A systematic review.灭活疫苗Covaxin/BBV152：一项系统评价。
Front Immunol. 2022 Aug 9;13:863162. doi: 10.3389/fimmu.2022.863162. eCollection 2022.
6
Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.接种 Covishield 和辉瑞 SARS-CoV-2 疫苗可引发强烈的体液免疫反应。
J Infect Dev Ctries. 2021 May 31;15(5):653-656. doi: 10.3855/jidc.15368.
7
Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses.科瓦欣/BBV152 疫苗加强免疫可引起全身性细胞因子和趋化因子反应增强。
Front Immunol. 2021 Oct 15;12:752397. doi: 10.3389/fimmu.2021.752397. eCollection 2021.
8
Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?针对 COVID-19 的异源初免-加强接种：安全且可靠吗？
Hum Vaccin Immunother. 2021 Dec 2;17(12):5135-5138. doi: 10.1080/21645515.2021.2007015. Epub 2021 Dec 13.
9
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.异源 ChAdOx1-nCoV-19/mRNA-1273 疫苗接种与同源 ChAdOx1-nCoV-19 或同源 mRNA-1273 疫苗接种的免疫反应和安全性比较。
J Formos Med Assoc. 2022 Apr;121(4):766-777. doi: 10.1016/j.jfma.2022.02.020. Epub 2022 Mar 16.
10
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.mRNA-1273 对 SARS-CoV-2 变异株的血清中和活性。
J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22.
引用本文的文献
1
Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection.新冠疫苗中和抗体反应和保护作用的比较持续时间以及保护相关因素。
Nat Commun. 2025 May 22;16(1):4748. doi: 10.1038/s41467-025-60024-9.
2
Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.针对 SARS-CoV-2 奥密克戎变异株的中和抗体反应：接种 ChAdOx1 nCoV-19 或 BBV152 两剂和三剂疫苗后 6 个月。
Indian J Med Res. 2024 Feb 1;159(2):223-231. doi: 10.4103/ijmr.ijmr_948_23. Epub 2024 Apr 4.
3
Analysis of SARS-CoV-2 genome evolutionary patterns.分析 SARS-CoV-2 基因组的进化模式。
Microbiol Spectr. 2024 Feb 6;12(2):e0265423. doi: 10.1128/spectrum.02654-23. Epub 2024 Jan 10.
4
Acceptance of Annual Booster Doses of COVID-19 Vaccines Among Indian Healthcare Professionals: A Pan-India Cross-Sectional Survey.印度医疗保健专业人员对新冠疫苗年度加强剂量的接受情况：一项全印度横断面调查。
Cureus. 2023 Nov 24;15(11):e49363. doi: 10.7759/cureus.49363. eCollection 2023 Nov.
5
Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines.观察 SARS-CoV-2 和 SARS-CoV 的 T 细胞免疫：相信基于表位的疫苗。
Int J Biol Sci. 2023 Aug 6;19(13):4052-4060. doi: 10.7150/ijbs.80468. eCollection 2023.
6
Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform.在印度，对野生型（B.1）病毒、Kappa（B.1.617.1）和 Delta（B.1.617.2）变体以及 COVISHIELD 疫苗免疫的自然感染中，针对 10 种 SARS-CoV-2 变体的可变中和抗体反应：MSD 平台的实用性。
Front Immunol. 2023 Jun 5;14:1181991. doi: 10.3389/fimmu.2023.1181991. eCollection 2023.
7
An update on SARS-CoV-2 immunization and future directions.新型冠状病毒2型免疫接种的最新情况及未来方向。
Front Pharmacol. 2023 Mar 9;14:1125305. doi: 10.3389/fphar.2023.1125305. eCollection 2023.
8
Inactivated vaccine Covaxin/BBV152: A systematic review.灭活疫苗Covaxin/BBV152：一项系统评价。
Front Immunol. 2022 Aug 9;13:863162. doi: 10.3389/fimmu.2022.863162. eCollection 2022.
9
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.奥密克戎变异株 COVID-19 疫苗的体液和细胞免疫应答：系统评价。
Int J Biol Sci. 2022 Jul 11;18(12):4629-4641. doi: 10.7150/ijbs.73583. eCollection 2022.
Zotero 插件